Target intelligence / Profile preview

Solute carrier family 25 member 22 mRNA 3′-untranslated region (SLC25A22 mRNA 3′-UTR) (SLC25A22 mRNA 3′-UTR)

Target
SLC25A22 mRNA 3′-UTR
Molecular classification
Untranslated region, Regulatory RNA element, Messenger RNA
01

Overview

The SLC25A22 mRNA 3′-untranslated region (3′-UTR) is a critical regulatory segment of the messenger RNA that encodes the mitochondrial glutamate carrier 1 (GC1). This region serves as a primary site for post-transcriptional control, where it interacts with microRNAs (miRNAs) and RNA-binding proteins to modulate the stability and translation of the SLC25A22 transcript (1.2.2, 1.4.3). A key regulator of this 3′-UTR is miR-184, which binds to specific recognition elements to induce mRNA degradation or repress protein synthesis, thereby influencing cellular processes such as insulin secretion and tumor cell metabolism (1.2.2, 1.4.1). SLC25A22 itself is essential for transporting glutamate into the mitochondrial matrix, a process vital for the tricarboxylic acid (TCA) cycle and amino acid biosynthesis (1.3.1, 1.3.5). In oncology, the SLC25A22 mRNA 3′-UTR is an emerging therapeutic target; for instance, using miR-184 mimics to target this region has been shown to reduce radioresistance and aggressiveness in glioblastoma (1.4.1). Conversely, mutations in the SLC25A22 gene are linked to severe neonatal epileptic encephalopathies, highlighting the importance of precise regulation of this carrier for normal neurological function (1.1.1, 1.3.2).

Other names
SLC25A22 3'-UTRGC1 3'-UTRMitochondrial glutamate carrier 1 3'-UTRSolute carrier family 25 member 22 3'-UTRGC1 mRNA 3'-UTR
02

Mechanism of action

MicroRNA-mediated gene silencing, RNA interference (RNAi), and translational inhibition leading to reduced protein expression.

03

Biological functions

Post-transcriptional regulationmRNA stability controlTranslational repressionGene expression regulation
04

Disease associations

GlioblastomaColorectal cancerEarly infantile epileptic encephalopathy 3Type 2 diabetesOsteosarcomaMigrating partial seizures in infancy
05

Safety considerations

Off-target silencing of unintended mRNA transcriptsPotential for systemic metabolic disruption due to inhibition of mitochondrial glutamate transportRisk of neurological side effects given the target's role in brain development and seizure regulation
06

Interacting drugs

miR-184 mimic

2 more in the full profile.

07

Biomarkers

SLC25A22 mRNA expression levelsmiR-184 expression levelsMitochondrial glutamate transport activity

Beyond the preview

Go deeper on Solute carrier family 25 member 22 mRNA 3′-untranslated region (SLC25A22 mRNA 3′-UTR) (SLC25A22 mRNA 3′-UTR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 25 member 22 mRNA 3′-untranslated region (SLC25A22 mRNA 3′-UTR) (SLC25A22 mRNA 3′-UTR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call